Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
July 11 2022 - 1:00PM
Oxurion Announces Presentations at Upcoming Scientific and Investor
Conferences
Leuven, BELGIUM, Boston, MA, US
– July
11, 2022 – Oxurion NV (Euronext Brussels:
OXUR) a biopharmaceutical company developing next generation
standard of care ophthalmic therapies, with clinical stage assets
in vascular retinal disorders, announced today participation in two
upcoming conferences.
American Society of Retina Specialists 2022 Annual
Meeting – New York, NYDate: Saturday,
July 16, 2022 | 1:29 p.m. ET
Title: “A Phase 2 study of THR-149, a Plasma
Kallikrein Inhibitor, in Subjects with DME who Respond Suboptimally
to anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI
study),” presented by Rahul Khurana, MD.
THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of diabetic macular edema (DME) patients showing suboptimal
response to anti-VEGF therapy. Oxurion is evaluating THR-149 for
the treatment of DME in Part B, the second part of its two-part
Phase 2 KALAHARI trial.
H.C. Wainwright & Co., 2nd Annual Ophthalmology
Virtual ConferenceDate: Wednesday, August 17, 2022 |
On-demand Tom Graney, CEO of Oxurion, is available for one-on-one
meetings and will deliver a pre-recorded presentation, available
on-demand.
Both presentations will be available in the “Investors” section
of the Company’s website.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 479 783583michael.dillen@oxurion.com |
USConway CommunicationsBeth Kurthbkurth@conwaycommsir.com
ICR WestwickeChristopher BrinzeyTel: +1 617 835
9304Chris.Brinzey@westwicke.com |
- OXUR Upcoming Conferences 2022.0711 FINAL
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2023 to Apr 2024